DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0073103 A1 Guck Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0073103 A1 Guck Et Al US 200600731 03A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0073103 A1 Guck et al. (43) Pub. Date: Apr. 6, 2006 (54) CONTROLLED DOSAGE AEROSOLS WITH (30) Foreign Application Priority Data LECT HINAS SURFACE-ACTIVE AGENT Dec. 24, 2002 (DE)..................................... 102 6O 8822 (76) Inventors: Franz Guck, Rheinfelden (DE): Gieselher Warnke, Herrischried (DE) Publication Classification Correspondence Address: (51) Int. Cl. D Peter Hochberg A6IL 9/04 (2006.01) 1940 East 6th Street A 6LX 3/573 (2006.01) 6th Floor (52) U.S. Cl. .............................................. 424/45: 514/179 Cleveland, OH 44114 (US) (21) Appl. No.: 10/540,648 (57) ABSTRACT (22) PCT Filed: Dec. 24, 2003 A controlled dosage aerosol containing at least one medici nal agent, pressure-liquefied isobutane as the propellant, and (86). PCT No.: PCT/EPO3/14901 lecithin as the Surfactant. US 2006/00731 03 A1 Apr. 6, 2006 CONTROLLED DOSAGE AEROSOLS WITH 0010 DE 1991 1 064 discloses controlled dosage aero LECT HINAS SURFACE-ACTIVE AGENT sols containing broncholytic and/or anti-inflammatory agents from the group of the glucocorticoids, with isobutane CROSS-REFERENCE TO RELATED as propellant and oleic acid or Span 85 as Surface-active APPLICATIONS Substances. These dosage aerosols, however, have the dis 0001. This application is a National Stage application of advantage of a dissatisfactory resuspensibility and of too International Application No. PCT/EP2003/014901, filed on quick a sedimentation of the active Substance in the propel Dec. 24, 2003, which claims priority of German application lant. number 102 60882.2, filed on Dec. 24, 2002. SUMMARY OF THE INVENTION BACKGROUND OF THE INVENTION 0011. An object of the present invention to provide a controlled dosage aerosol for medicinal agents, especially 0002) 1. Field of the Invention for anti-asthmatic medicinal agents from the group of the 0003. The subject matter of the present invention is glucocorticoids which does not have the disadvantages of controlled dosage aerosols which comprise at least one the controlled dosage aerosols known from DE 1991 1 064. medicinal agent as well as a mixture made of pressure liquefied isobutane as propellant and lecithin as Surface DETAILED DESCRIPTION OF THE active agent. INVENTION 0004 The present invention more particularly relates to 0012. It was surprisingly found that the adjuvant lecithin controlled dosage aerosols comprising at least one medicinal leads to a marked improvement of the resuspensibility of agent with anti-asthmatic action from the group of the medicinal agents, especially of glucocorticoids in isobutane. glucocorticoids as well as a mixture made of pressure 0013 Lecithins are glycerophospholipides that are made liquefied isobutane as propellant and lecithin. from fatty acids, glycerol, phosphoric acid and choline. 0005 2. Description of the Prior Art Naturally occurring lecithins are derivatives of 1,2-diacyl sn-glycerol-3-phosphoric acid. When extracting lecithin 0006 Aerosol pressurized gas packs, also called con from biological material one always obtains a mixture of trolled dosage aerosols or metered aerosols for short, which are produced and employed by using liquefied pressure lecithins that differ from each other by the different fatty acid gases or compressed gases as a propellant, have been known eSterS. for a long time. Generally, Such metered aerosols consist of 0014. According to the present invention, an advanta a pressure vessel. Such as of metal or glass, having a valve geous lecithin is soybean lecithin, which is already widely construction for withdrawing its content, and of the actual used in the pharmaceutics industry as an emulsifier. agent to be sprayed, which in most cases consists of an 0015. In a comparison of the sedimentation behaviour of active Substance solution as well as a propellant in the form Suspensions of medicinal agent in isobutane under addition of a gas or a gas mixture liquefied under pressure. The of soybean lecithin or various Surface-active agents com pressure-liquefied gas or pressure-liquefied gas mixtures monly employed in the production of anti-asthmatic metered should ideally be miscible with the active substance at any aerosols it was observed, as will be seen from the below ratio So that one single liquid phase is formed. As an example, that the medicinal agent Suspension with soybean alternative, the pressure-liquefied gas or gas mixture should lecithin took 10 times longer to sediment than a medicinal form a Suspension with the active Substance which can be agent Suspension with oleic acid, and 5 times longer than a shaken easily and above which a gas phase forms. Depend medicinal agent Suspension with Span 85. ing on the agent contained, these metered aerosols are used in the cosmetic and medical fields, or as a room spray, 0016. In further tests, with a ratio of medicinal agent to insecticidal spray, and the like. soybean lecithin of 1:2, 1:1 or 1:0.5, no differences were observed in the sedimentation time, so that a ratio of 0007. The propellants of controlled dosage aerosols have medicinal agent to soybean lecithin of 1:0.5 may advanta to satisfy special requirements. They must by no means react geously be chosen. with the components of the active agent solution. Also, the propellants must be non-irritating and non-toxic. Fluoro chlorinated hydrocarbons had proved particularly suitable. EXAMPLE However, because of their ozone-depleting effect it has been 0017 Comparison of the suspension behaviour of sus necessary to develop alternative propellants. pensions of medicinal agent in isobutane, using various 0008 However, the quality of these alternative agents Surface-active agents must be comparable to that of the fluorochlorinated hydro carbons; above all, they must be both non-injurious to health and ecologically compatible. Initially, partially halogenated Relative fluorochlorinated hydrocarbons were frequently propagated sedimentation as replacements but these still have an unacceptably high Glucocorticoid:oleic acid (100:1) 1 oZone-depleting ability. Glucocorticoid:Span 85 (1:1) 2 Glucocorticoid:soybean lecithin (1:2) 10 0009. DE 4132 176 discloses controlled dosage aerosols Glucocorticoid:soybean lecithin (1:1) 10 for administering isoprenalin derivatives, the so-called Glucocorticoid:soybean lecithin (1:0.5) 10 B-sympathomimetics, or the non-steroid anti-inflammatory agent DNCG wherein isobutane is employed as a propellant. US 2006/00731 03 A1 Apr. 6, 2006 0018. In further tests, the following formulations have 2. The controlled dosage aerosol according to claim 1, turned out to be especially advantageous: wherein said at least one medicinal agent is at least one glucocorticoid selected from the group consisting of corti Sol, prednisone, prednisolone, methylprednisolone, triamci Formulation 1: Glucocorticoid O.1% 0.2% nolone, prednylidene, fluocortolone, paramethasone, dex Lecithin O.05% 0.4% amethasone, betamethasone, flunisolide, fluticaSone, Isobutane 99.85% 99.4% Formulation 2: Glucocorticoid O.S96-1.0% beclomethasone, budesonide and anti-asthmatically active Lecithin O.25% 4.0% derivatives thereof. Isobutane 99.75% 95.0% 3. The controlled dosage aerosol according to claim 1, wherein said controlled dosage aerosol comprises glucocor 0.019 For the glucocorticoid beclomethasone diproprion ticoid in the amount of 0.1%-0.2%, lecithin in the amount of ate, the following formulation has been found useful: 0.05%-0.4% and isobutane in the amount of 99.85%-99.4%. 4. The controlled dosage aerosol according to claim 1, wherein said controlled dosage aerosol comprises glucocor Formulation 3: Becomethasone O.1%. 2.5% ticoid in the amount of 0.5%-1.0%, lecithin in the amount of Soybean lecithin O.05% 5.0% 0.25%-4.0% and isobutane in the amount of 99.75%-95.0%. Isobutane 99.85% 92.5% 5. The controlled dosage aerosol according to claim 1, wherein said lecithin is soybean lecithin. 0020 For budesonide the following formulation has been 6. The controlled dosage aerosol according to claim 1, found extremely useful: wherein said controlled dosage aerosol comprises beclom ethasone in the amount of 0.1%-2.5.0%, soybean lecithin in the amount of 0.05%-5.0% and isobutane in the amount of Formulation 4: Budesonide O.1%. 2.5% 99.85%-92.5%. Soybean lecithin O.05% 5.0% 7. The controlled dosage aerosol according to claim 1, Isobutane 99.85% 92.5% wherein said controlled dosage aerosol comprises budes onide in the amount of 0.1%-2.5.0%, soybean lecithin in the 0021 All quantities relate to percent by weight. amount of 0.05%-5.0% and isobutane in the amount of 0022. The inventive aerosols may be prepared by mixing 99.85%-92.5%. the various components under conditions in which the 8. The controlled dosage aerosol according to claim 5, propellant and the Surfactant are liquid and in which the wherein the ratio of glucocorticoid and Soybean lecithin is active agent is present in a Solid phase. 1:2. 0023 The suspension of medicinal agent is filled through 9. The controlled dosage aerosol according to claim 1 for the valve into the clinched tin under pressure, which tin at treating allergic diseases in humans and animals. the beginning of the filling process has room temperature. 10. The controlled dosage aerosol according to claim 1 for The suspension has a temperature of approx. -10 to +10°C. treating asthma or allergic rhinitis. Subsequently, the tin is filled up with the propellant, thereby cleaning the valve at the same time. 11. A process for the production of controlled dosage aerosols according to claim 1, comprising the steps of: 0024. The controlled dosage aerosols according to the present invention may be used in the treatment of humans mixing isobutane as a propellant in liquid form, lecithin as and animals, in particular in the treatment of allergic dis a Surface-active agent in liquid form, and at least one eases of the respiratory tract, Such as asthma or allergic medicinal agent as Solid Substance to form a liquid rhinitis (hay fever).
Load more

Recommended publications
  • Ep 0173478 A1
    Patentamt JEuropaischesJ European Patent Office @ Publication number: 0173 478 ^ ^ Office europeen des brevets EUROPEAN PATENT APPLICATION Application number: 85305552.3 © 'nt. CI ": A 61 K 35/78, A 61 K 31 /57 Dateof filing: 05.08.85 (A61K35/78, 31 :57),(A61K31/57, 31 :23, 31 :20) @ Priority: 15.08.84 GB 8420771 @ Applicant: EFAMOL LIMITED, Efamol House Woodbridge Meadows, Guildford Surrey GU1 1BA (GB) @ Date of publication of application: 05.03.86 @ Bulletin 86/10 efamol House woodbridge meadows, Guildford Surrey GU1 1BA (GB) @ Representative : Caro, William Egerton et al, J. MILLER & @ Designated Contracting States: AT BE CH DE FR GB IT CO. Lincoln House 296-302 High Holborn, London LILUNLSE WC1V7JH(GB) @ Treatment of skin disorders. A topical composition for skin treatment contains an anti- inflammatory glucocorticoid in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent poly- unsaturated fatty acid, as such or in the form of a physio- logically acceptable derivative convertible in the body thereto. FIELD OF INVENTION The invention relates to compositions of y-linolenic acid and related materials with anti-inflammatory glucocorticoids and to the treatment of inflammatory skin disorders with them. BACKGROUND AND EXPLANATION OF INVENTION Much interest has been shown in recent years in essential fatty acid metabolism, especially in its relation to prosta- glandin (PG) metabolism and in particular to the balance of 1-series and 2-series PGs in the body. The main dietary essential fatty acid (EFA) utilised in the fully healthy human body is linoleic acid, but the Δ6- desaturase that converts it to the next acid in the n-6 series, namely y-linoleic acid (GLA) is at a low level of activity in many conditions.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al
    US007544192B2 (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton et al. (45) Date of Patent: Jun. 9, 2009 (54) SINUS DELIVERY OF SUSTAINED RELEASE 5,443,498 A 8, 1995 Fontaine THERAPEUTICS 5,512,055 A 4/1996 Domb et al. 5,664,567 A 9, 1997 Linder (75) Inventors: Donald J. Eaton, Woodside, CA (US); 5,693,065. A 12/1997 Rains, III Mary L. Moran, Woodside, CA (US); 5,792,100 A 8/1998 Shantha Rodney Brenneman, San Juan Capistrano, CA (US) (73) Assignee: Sinexus, Inc., Palo Alto, CA (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 992 days. WO WOO1/02024 1, 2001 (21) Appl. No.: 10/800,162 (22) Filed: Mar 12, 2004 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2005/OO437O6A1 Feb. 24, 2005 Hosemann, W. et al. (Mar. 2003, e-pub. Oct. 10, 2002). “Innovative s Frontal Sinus Stent Acting as a Local Drug-Releasing System.' Eur: Related U.S. Application Data Arch. Otorhinolarynolo. 260:131-134. (60) Provisional application No. 60/454,918, filed on Mar. (Continued) 14, 2003. Primary Examiner Kevin C Sirmons (51) Int. Cl Assistant Examiner Catherine NWitczak A. iM sI/00 (2006.01) (74) Attorney, Agent, or Firm Morrison & Foerster LLP (52) U.S. Cl. ........................ 604/506; 604/510; 604/514 (57) ABSTRACT (58) Field of Classification Search .............. 604/93.01, 604/891.1. 890.1, 57, 59-64, 510, 514,506; S lication file f 606/196 The invention provides biodegradable implants for treating ee application file for complete search history.
    [Show full text]
  • Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of Ro5459072 in Patients with Primary Sjögren’S Syndrome
    Official Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME NCT Number: NCT02701985 Document Dates: Protocol Version 3: 30-Oct-2016 PROTOCOL TITLE: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME PROTOCOL NUMBER: BP30037 VERSION: 3 EUDRACT NUMBER: 2015-004476-30 IND NUMBER: 128528 TEST PRODUCT: RO5459072 SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 28 January 2016 DATE AMENDED Version 2: 01 August 2016 Version 3: See electronic date stamp below FINAL PROTOCOL APPROVAL Approver's Name Title Date and Time (UTC) Translational Medicine Leader 30-Oct-2016 15:40:47 CONFIDENTIAL STATEMENT The information contained in this document, especially any unpublished data, is the property of F.Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. RO5459072— F. Hoffmann-La Roche Ltd Protocol BP30037 Version 3 PROTOCOL AMENDMENT, VERSION 3: RATIONALE Protocol BP30037 has been amended to incorporate the following changes to the protocol: Section 4.2.3: Implementation of changes to eligibility criteria . The eligibility criteria of the protocol have therefore been amended to mandate testing for tuberculosis and exclude patients with positive results.
    [Show full text]
  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T (51) International Patent Classification: (74) Common Representative: UNIVERSITY OF VETER¬ A61K 9/06 (2006.01) A61K 47/32 (2006.01) INARY AND PHARMACEUTICAL SCIENCES A61K 9/14 (2006.01) A61K 47/38 (2006.01) BRNO FACULTY OF PHARMACY; University of A61K 47/10 (2006.01) A61K 9/00 (2006.01) Veterinary and Pharmaceutical Sciences Brno Faculty Of A61K 47/18 (2006.01) Pharmacy, Palackeho 1/3, CZ-61242 Brno (CZ). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/CZ20 12/000073 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 August 2012 (02.08.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, 201 1-495 11 August 201 1 ( 11.08.201 1) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 2012- 72 1 February 2012 (01.02.2012) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2012-5 11 26 July 2012 (26.07.2012) ZW.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Adalimumab for Maintenance of Clinical Response and Remission
    GASTROENTEROLOGY 2007;132:52–65 Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial ALIMENTARY TRACT CLINICAL– JEAN–FRÉDÉRIC COLOMBEL,* WILLIAM J. SANDBORN,‡ PAUL RUTGEERTS,§ ROBERT ENNS,ʈ STEPHEN B. HANAUER,¶ REMO PANACCIONE,# STEFAN SCHREIBER,** DAN BYCZKOWSKI,‡‡ JU LI,§§ JEFFREY D. KENT,‡‡ and PAUL F. POLLACK‡‡ *Department of Hepatogastroenterology, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France; ‡Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; §Department of Gastro-Enterologie, University Hospital of Gasthuisberg, Leuven, Belgium; ʈDepartment of Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada; ¶Section of Gastroenterology, University of Chicago, Chicago, Illinois; #Department of Medicine, Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada; **Department of General Internal Medicine and Institute for Clinical Molecular Biology, Christian-Albrechts University, Kiel, Germany; ‡‡Department of Immunology Development, Abbott Laboratories, Parsippany, New Jersey; and §§Department of Biostatistics and Data Management, Abbott Laboratories, Abbott Park, Illinois umor necrosis factor (TNF) is an important cytokine See Turner D et al on page 103 for companion Tin the pathogenesis of Crohn’s disease (CD), with article in Clin Gastroenterol Hepatol. elevated concentrations playing a role in pathologic in- flammation.1,2 Clinical trials have demonstrated
    [Show full text]
  • United States Patent (10) Patent No.: US 9.447,027 B2 Milan Et Al
    US009447027B2 (12) United States Patent (10) Patent No.: US 9.447,027 B2 Milan et al. (45) Date of Patent: Sep. 20, 2016 (54) TREATING LONG QT SYNDROME 2004/O1972.71 A1* 10, 2004 Kunka et al. ................... 424/45 2006/0173058 A1* 8, 2006 Brown .................... CO7C 65/05 514,381 (75) Inventors: Es l, St. MS 2006/0173508 A1* 8, 2006 Stone ................. A61N 1,36085 aVId S. Peal, SomerV11 le. (US) 607/40 (73) Assignee: The General Hospital Corporation, FOREIGN PATENT DOCUMENTS Boston, MA (US) JP 11209328 A1 * 8, 1999 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 86 days. Nademanee, K. et al., Annals of the New York Academy of Sciences vol. 522, pp. 536-552, published 2006.* (21) Appl. No.: 13/822,264 Chouabe, C. et al., Molecular Pharmacology vol. 54 pp. 696-703, published 1998.* (22) PCT Filed: Oct. 20, 2011 Nishizawa, S., et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.e1-1167.e3, published Nov. 2009).* (86). PCT No.: PCT/US2011/057087 Nishizawa et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.el -1167.e3, published Nov. 2009).* S 371 (c)(1), Nishizawa et al (American Journal of Emergency Medicine vol. 27. (2), (4) Date: Jul. 22, 2013 pp. 1167.e1-1167.e3, published Nov. 2009).* Anderson et al., “Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism.” Circula (87) PCT Pub. No.: WO2012/054718 tion 113:365-373, 2006, 10 pages.
    [Show full text]
  • Chronic Immune-Mediated Inflammatory Diseases
    Supplementary Table 1 Diagnoses included in each group ICD-10 Code Title K50-K52 Inflammatory bowel diseases K50 Crohn disease (regional enteritis) K51 Ulcerative colitis K52 Other noninfective gastroenteritis and colitis M05-M14, L40.5 Inflammatory polyarthropathies M05 Seropositive rheumatoid arthritis M06 Other rheumatoid arthritis M07 Psoriatic and enteropathic arthropathies M08 Juvenile arthritis M09 Juvenile arthritis in diseases classified elsewhere M10 Gout M11 Other crystal arthropathies M12 Other specific arthropathies M13 Other arthritis L40.5 Arthropathic psoriasis M30-M35, G635 Systemic connective tissue disorders M30 Polyarteritis nodosa and related conditions M31 Other necrotizing vasculopathies M32 Systemic lupus erythematosus M33 Dermatopolymyositis M34 Systemic sclerosis M35 Other systemic involvement of connective tissue G63.5 Polyneuropathy in systemic connective tissue disorders M45-M46 Spondylopathies M45 Ankylosing spondylitis M46 Other inflammatory spondylopathies Supplementary Table 2 Outcomes considered in the follow-up ICD-10 Code Title I20-I23, I25 Ischemic heart diseases I20 Angina pectoris I21 Acute myocardial infarction I22 Subsequent myocardial infarction I23 Certain current complications following acute myocardial infarction I25 Chronic ischaemic heart disease I60-I64 Cerebrovascular diseases I60 Subarachnoid hemorrhage I61 Intracerebral haemorrhage I62 Other nontraumatic intracranial haemorrhage I63 Cerebral infarction I64 Stroke, not specified as haemorrhage or infarction Supplementary Table 3 DMARDS
    [Show full text]
  • Index Vol. 16-23
    233 Index Vol. 16-23 The references of the Subject Index are given in the language of the respective contribution. Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgeftihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. A 17 Abortion, therapeutic 457,460 23 Acetylsalicylic acid (Aspirin®) 114 20 Academic research 169 16 O-Acetylserin-Sulfhydrylase A 390 18 Acanthocheilonema perstans 142 17 Acetylstrophanthidin 35 18 Acanthocheilonema streptocerca 142 22 Achromycin® (tetracycline) 53 22 Acaprin® (quinuronium sulfate) 42 19 Acidosis 529 20 Acebutolol 33, 36, 229 18 Acid phosphotase 66 18 Acedapson (Hansolar®, 4',4"'-sulfonylbis­ 16 Aconitase-Isomerase 436 acetanilide) 108, 156 17 Aconitine 35,46 17 Acedist® (bromfenofos, Ph 1882) 113, 134, 17 Acranil 119, 152 278 17 Acrichine® (quinacrine) 119 18 Aceperone 437 17 Acridine 295 16 Acetacetat-Decarboxylase 414 16 Acriftavin 100 17 2-Acetamido-5-nitrothiazole 261 17 Acrolein 358 17 Acetanilide 23, 497 18 Acronine 440 20 Acetanilide 400 21 Acrosin 366 23 Acetanilide 212 21 Acrylamide 186 20 Acetazolamide (Diamox®) 209,417 17 Actamer® (bithionol) 114,297 21 - 114 22 Actamer® (bithionol) 46 22 Acetohexamide (Dymelor®) 81 16 Actinomycin I 298 17 Acetohydroxamic acid 348 16 Actinomycin IV 298 17 Acetone 13, 17 16 Actinomycin V 298 16 Acetophenone 260 17 Actinomycin C, (actinomycin D) 376 17 2-Acetoxy-4' -chloro-3,5-diiodobenzanilide 16 Actinomycin D (actinomycin C" (clioxanide) 114,135,164,277,281
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Transactivation Via the Human Glucocorticoid And
    European Journal of Endocrinology (2004) 151 397–406 ISSN 0804-4643 EXPERIMENTAL STUDY Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties Claudia Grossmann1, Tim Scholz1, Marina Rochel1, Christiane Bumke-Vogt1, Wolfgang Oelkers1, Andreas F H Pfeiffer1,2, Sven Diederich1,2 and Volker Ba¨hr1,2 1Department of Endocrinology, Diabetes and Nutrition, Charite´-Universita¨tsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany and 2Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam, Bergholz-Rehbru¨cke, Germany (Correspondence should be addressed to Volker Ba¨hr, Department of Endocrinology, Diabetes and Nutrition, Charite´-Universita¨tsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany; Email: [email protected]) Abstract Background: Glucocorticoids (GCs) are commonly used for long-term medication in immunosuppressive and anti-inflammatory therapy. However, the data describing gluco- and mineralo-corticoid (MC) properties of widely applied synthetic GCs are often based on diverse clinical observations and on a var- iety of in vitro tests under various conditions, which makes a quantitative comparison questionable. Method: We compared MC and GC properties of different steroids, often used in clinical practice, in the same in vitro test system (luciferase transactivation assay in CV-1 cells transfected with either hMR or hGRa expression vectors) complemented by a system to test the steroid binding affinities at the hMR (protein expression in T7-coupled rabbit reticulocyte lysate). Results and Conclusions: While the potency of a GC is increased by an 11-hydroxy group, both its potency and its selectivity are increased by the D1-dehydro-configuration and a hydrophobic residue in position 16 (16-methylene, 16a-methyl or 16b-methyl group).
    [Show full text]